A retrospective multicenter study assessing usage patterns, safety and efficacy outcomes, and resource utilization in Relapsed/Refractory Aggressive B Cell Lymphomas
Latest Information Update: 28 Oct 2022
At a glance
- Drugs Axicabtagene ciloleucel (Primary) ; Tisagenlecleucel (Primary)
- Indications B-cell lymphoma
- Focus Therapeutic Use
Most Recent Events
- 28 Oct 2022 New trial record
- 01 Oct 2022 Results published in the Transplantation and Cellular Therapy